• Quotes
  • Shortcuts
The Executive's Internet
Mon, Jan 25th
icon
GoogleAmazonWikipedia


spacerspacer

 

 BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'Stocks'. (Return)

MarketWatchJan 25, 2021
Metals Stocks: Gold prices perk up as government bond yields retreat
Futures for gold on Monday head modestly higher as government bond yields were pulling back.

MarketWatch MarketPulseJan 25, 2021
Moderna: Lab study confirms its COVID-19 vaccine still protects against new variants
Shares of Moderna Inc. gained 4.6% in premarket trading on Monday afer the company said laboratory studies demonstrated that its COVID-19 vaccine can still protect people against two new coronavirus variants: the B.1.1.7 that was first identified in the United Kingdom, and the B.1.351 strain, out of South Africa. The study was not conducted in humans. The findings were released in a news release, and the company said it expects the results to be published in preprint form. Moderna said the in-vitro studies showed that the B.1.1.7 variant had no "significant" impact on neutralizing antibody titers developed as a result of vaccination; however, they also demonstrated that the vaccine was less effective against the B.1.351 variant. In this case, the vaccine still produced levels of neutralizing antibody titers that were protective, but the titer levels were lower. Moderna said it now plans to study booster doses for its two-dose COVID-19 vaccine, to see if a third dose of some kind can increase neutralizing antibody titers and if a booster can specifically protect against the B.1.351 variant. This booster, mRNA-1273.351, will be tested in preclinical studies and a Phase 1 study in the U.S. The U.K. and South Africa variants have caused concern from government officials and medical experts around the world because they are more infectious and carry a higher viral load than other strains of the virus. Moderna's stock has gained 520.3% over the past 12 months, while the S&P 500 is up 15.6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



Yahoo BusinessJan 25, 2021
Goldman Sachs warns of a dangerous bubble in these 39 stocks


MarketWatch MarketPulseJan 25, 2021
GameStop shares surge 44% in premarket trade as epic run continues
GameStop shares surged 44% in early premarket action, after storming 51% higher on Friday. The spectacular gains came after short-selling firm Citron Research and speculative buyers organizing on Reddit clashed over the video-games retailer. After the markets closed on Friday, Citron released a video arguing the stock was worth $20.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



The Motley FoolJan 25, 2021
2 Stocks to Buy With Dividends Yielding More Than 4%
These two REITs have a history of raising dividends and managing their operations well in good times and bad.

RELATED ARTICLES
Kimberly-Clark stock gains after profit and sales beats, raised dividend and new stock buyback program (MarketWatch MarketPulse)
Is Stitch Fix Stock a No-Brainer Buy? (The Motley Fool)

MarketWatch MarketPulseJan 25, 2021
CDC: Moderna's COVID-19 vaccine can cause allergic reaction in some people
The Centers for Disease Control and Prevention said Friday that Moderna Inc.'s COVID-19 vaccine produces an allergic reaction in a small percentage of people, similar to the agency's findings about the coronavirus vaccine developed by BioNTech SE and Pfizer Inc. . Moderna's stock was up 1.6% in premarket trading on Monday. There were 10 cases of anaphylaxis among the roughly 4 million doses administered between Dec. 21 and Jan. 10, according to the CDC report. Both vaccines are mRNA-based vaccines, with similar efficacy rates in clinical trials. They are the only two COVID-19 vaccines that have been authorized in the U.S. so far during the pandemic. The CDC previously recommended that health care providers prepare for the possibility of anaphylaxis among some people who get vaccinated. Moderna's stock has soared 520.3% over the past 12 months, while the S&P 500 is up 15.6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



MarketWatch MarketPulseJan 25, 2021
Telus International sets IPO terms, to be valued at up to $5.6 billion
Telus International Inc. has set terms for its initial public offering, in which the Canada-based telecommunications company looks to raise up to about $548.2 million. The company is offering 21.93 million shares in the IPO, while selling shareholders are offering 11.40 million shares, for a total of 33.33 million shares offered. The IPO is expected to price between $23 and $25 a share. With 223.73 million shares outstanding after the IPO, the pricing values the company at up to $5.59 billion. The company has applied for its shares to list on the New York Stock Exchange and the Toronto Stock Exchange, under the ticker symbol "TIXT." J.P. Morgan and Morgan Stanley are the lead bookrunners of the IPO. For the nine months ended Sept. 30, the company reported net income of $81.9 million on revenue of $1.14 billion, after net income of $41.7 million on revenue of $747.1 million in the year-ago period. The company is looking to go public at a time that the Renaissance IPO ETF has rallied 30.0% over the past three months while the S&P 500 has gained 10.9%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



MarketWatch MarketPulseJan 25, 2021
AMC shares soar 36% premarket on news of new $917 million debt and equity financing
AMC Entertainment Holdings Inc. shares soared 36% in premarket trade Monday, after the biggest cinema-chain operator in the world said it has raised $917 million in debt and equity to help it get through a coronavirus-impacted winter. AMC said it has raised $506 million of equity by issuing 164.7 million new shares. That is combined with a previously announced $100 million of additional first-lien debt and the concurrent issuance of 22 million new common shares to convert $100 million of second-lien debt into equity. The company has commitment letters for $11 million of incremental debt capital in place through mid-2023, unless repaid before then, through the upsizing and refinancing of a European revolving credit facility. The company may pay non-cash PIK (payment in kind) interest through the duration of the European debt. "Based on a variety of assumptions, including future attendance levels, the company estimates that its financial runway has been extended deep into 2021," AMC said in a statement. "AMC also is presuming that it will continue to make progress in its ongoing dialogue with theatre landlords about the amounts and timing of owed theatre lease payments." Chief Executive Adam Aron said the new financing means any talk of imminent bankruptcy "is completely off the table." AMC has repeatedly raised capital through the pandemic to bolster its liquidity and stay afloat. Shares have fallen 48% in the last 12 months, while the S&P 500 has gained 16.6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



MarketWatchJan 25, 2021
Europe Markets: Earnings help nudge European stocks higher, while airlines hit by Biden tightening restrictions
European stocks rose on Monday, with strong earnings and signs that California is reopening offsetting worries about the travel industry.

NYTimes BusinessJan 25, 2021
How Options Trading Could Be Fueling a Stock Market Bubble
A swell of individual investors are betting that stocks will go up. That enthusiasm is having a growing influence over the regular stock market itself.

MarketWatch MarketPulseJan 25, 2021
Merck to discontinue development of COVID-19 vaccines, focus on two investigational therapies
Merck said Monday it is discontinuing development of its two COVID-19 vaccine candidates following disappointing trial results, and will instead focus on the development of two investigational therapeutic candidates. The decision comes after a review of findings from Phase 1 studies of the vaccine candidates, named V590 and V591, in which immune responses were inferior to those seen following natural infection and in trials of other vaccine candidates. "Merck continues to advance clinical programs and to scale-up manufacturing for two investigational medicines, MK-7110 and MK-4482 (molnupiravir); molnupiravir is being developed in collaboration with Ridgeback Bio," the company said in a statement. The company is expecting to book a charge in the fourth quarter, but did not offer any further details. Merck is still planning to submit the results of the early-stage trial for publication in a peer-reviewed journal. Shares fell 1.2% premarket and are down 6% in the last 12 months, while the S&P 500 has gained 16.6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



MarketWatch MarketPulseJan 25, 2021
White House details the Buy American executive order Biden's due to sign
The White House on Monday announced the details of the new Buy American order that President Joe Biden will sign. The order will direct an increase in both the threshold and price preferences for domestic goods before the government can buy from a non-U.S. supplier. It also will create a director of Made-in-America at the Office of Management and Budget as well as increase oversight of waivers to domestic preference laws.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.


TRENDING TAGS
StockBuy Market Futures How Week
Bidentravel American reinstate ban Covid
CovidCOVID-19 Vaccine positive Biden Merck
COVID-19vaccine Positive Merck toll President
VaccineCOVID-19 Covid Merck Moderna how
BusinessHow Capital Insider Oil pandemic
Earningsweek Futures Apple Ahead Tesla
ChinaBillion IPO Evergrande Biden Love
capitalbusiness Shares Evergrande EV surge
StocksBuy these Goldman Sachs warns

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2021 CEOExpress Company LLC